• search hit 4 of 11
Back to Result List

Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence

  • Direct stimulation of soluble guanylate cyclase (sGC) is emerging as a potential new approach for the treatment of renal disorders. sGC catalyzes the formation of cyclic guanosine monophosphate (cGMP), deficiency of which is implicated in the pathogenesis of chronic kidney disease (CKD). Therefore, new classes of drugs sGC stimulators and activators are being investigated in preclinical models under conditions where nitric oxide is deficient. In preclinical models with different etiologies of CKD, the sGC stimulators BAY 41-2272, BAY 41-8543, BAY 60-4552, riociguat and vericiguat and the sGC activators cinaciguat, ataciguat, BI 703704 and GSK2181236A have shown consistently renoprotective effects. Clinical trials are required to confirm these findings in humans, and to ascertain whether these agents could provide a future alternative to guideline-recommended treatments.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Author:Johannes-Peter Stasch, Jens Schlossmann, Berthold HocherGND
ISSN:1471-4892 (print)
ISSN:1471-4973 (online)
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=25645316
Parent Title (English):Current opinion in pharmacology
Place of publication:Oxford
Document Type:Article
Year of first Publication:2015
Year of Completion:2015
Release Date:2017/03/27
First Page:95
Last Page:104
Funder:Bayer Pharma AG
Organizational units:Mathematisch-Naturwissenschaftliche Fakultät / Institut für Ernährungswissenschaft
Peer Review:Referiert